The group’s principle activity is to develop new antibiotics to combat the growing problem of drug resistance, as well as agents that improve the efficacy of current antibiotics. The group’s products include PZ-601 (also known as SMP-216601), Bactericidal Potentiators, and Efflux Pump Inhibitors. The group operates from United States.
